类他类药物,但不包括血管激素转化酶抑制剂,可以延缓大动脉狭窄症的进展
Raphael Rosenhek1, Florian Rader, Nicole Loho
1Department of Cardiology, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Wien, Austria. raphael.rosenhek@meduniwien.ac.at
Circulation
|September 1, 2004
概括
类药物显著减缓了大动脉狭窄症 (AS) 的进展,无论其严重程度如何. 抗胰岛素转化酶抑制剂 (ACEI) 似乎不会影响AS进展,即使与他类药物结合使用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 医学研究 医学研究
背景情况:
- 众所周知,他类药物和ACEI可以减缓大动脉的积.
- 以前的研究表明,他类药物可能会减少大动脉狭窄 (AS) 的血液动力学进展.
- 没有关于ACEI或联合治疗对AS进展的数据.
研究的目的:
- 调查ACEI和他类药物对AS血动力学进展的影响.
- 为了确定组合疗法是否比单一疗法提供额外的好处.
主要方法:
- 对211名具有先天性AS的患者进行了回顾性分析.
- 用于评估血液动力学进展 (峰值大动脉喷流速度) 的心声图.
- 根据治疗分类的患者:ACEI,他类药物,两者,或没有.
主要成果:
- 与不服用他类药物治疗 (0.39 m/s/y) 相比,他类药物显著降低了年度峰值大动脉喷流速度的增加 (0.10 m/s/y).
- 这种效应在轻度至中度和严重的AS中一致.
- 单独或与他类药物一起使用ACEI并没有显著影响AS进展.
结论:
- ACEI似乎没有减缓AS的血液动力学进展.
- 类药物显著降低AS的血液动力学进展,无论严重程度如何.
- 降胆固醇效应的他类药物可能不是减缓AS进展的主要机制.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


